In the claims

The following amendments are made with respect to the claims in the International application PCT/EP2003/007066.

This listing of claims will replace all prior versions and listings of claims in this application.

1 (Currently amended). A compound according to formula (1), or pharmaceutical acceptable salts or solvates thereof,

formula (1)



wherein:

R_1 is phenyl, substituted phenyl, C_5 to C_6 heteroaryl, C_5 to C_6 substituted heteroaryl, napthyl or substituted napthyl,

R_2 is H, C_1 to C_8 alkyl, C_1 to C_7 acyl, [[or]] C_1 to C_7 substituted acyl, C_1 to C_8 substituted alkyl, C_7 to C_{12} alkylphenyl, [[or]] C_7 to C_{12} substituted phenylalkyl, C_3 to C_8 cycloalkyl, C_3 to C_8 substituted cycloalkyl,[[,]] C_5 to C_6 heteroaryl, or [C_5 to C_6]-heteroaryl-(C_1 to C_6)-alkyl, and

R_3 is H, C_1 to C_8 alkyl, C_1 to C_8 substituted alkyl, C_7 to C_{12} alkylphenyl, ~~or or~~ C_7 to C_{12} substituted phenylalkyl, halogen, C_1 to C_8 alkoxy, furanyl, substituted furanyl, thiazyl, substituted thiazyl, carboxy, ester, amide or C_1 to C_8 aminoacyl.

2 (Currently amended). [[A]] The compound according to claim 1, or pharmaceutical acceptable salts or solvates thereof, wherein:

R_1 is phenyl, [[or]] substituted phenyl, C_5 to C_6 heteroaryl, or C_5 to C_6 substituted heteroaryl,

R_2 is H, CH_3, substituted alkyl or substituted phenyl, and

R_3 is substitute[[t]]d phenyl, C_5 to C_6 heteroaryl or C_5 to C_6 substituted heteroaryl.

3 (Currently amended). [[A]] The compound according to claim [[2]] 1, or pharmaceutical acceptable salts or solvates thereof, wherein:

R_1 is substituted phenyl,

R_2 is CH_3 or substituted alkyl, and

R_3 is substituted phenyl or substituted C_5 heteroaryl.

4 (Currently amended). [[A]] The compound according to claim 1, having the following formula (2)

formula (2)



wherein:

R_2 is H, C_1 to C_8 alkyl, C_1 to C_8 substituted alkyl, C_7 to C_{12} alkylphenyl or C_7 to C_{12} substituted phenylalkyl,

R_4 is H, C_1 to C_8 alkyl, halogen, C_1 to C_8 alkoxy, carboxy, ester, amide or C_1 to C_8 aminoacyl, and

R_5 is H, C_1 to C_8 alkyl, halogen, C_1 to C_8 alkoxy, carboxy, ester, amide or C_1 to C_8 aminoacyl.

5 (Currently amended). [[A]] The compound according to ~~any of~~ claim[[s]] 1 ~~to 4~~ having the following formula (3)

formula (3)



wherein:

R_2 is H, C_1 to C_7 acyl, [[or]] C_1 to C_7 substituted acyl, phenyl, substituted phenyl, C_5 to C_6 heteroaryl, C_5 to C_6 substituted heteroaryl, napthyl or substituted napthyl,

R_6 is H, C_1 to C_8 alkyl, C_1 to C_8 substituted alkyl, C_7 to C_{12} alkylphenyl, [[or]] C_7 to C_{12} substituted phenylalkyl, carboxy, ester, amide [[or]] C_1 to C_8 aminoacyl, or C_1 to C_8 alkoxy.

6 (Currently amended). [[A]] The compound according to ~~any of~~ claim[[s]] 1 ~~to 4~~ having the following formula (4)

formula (4)



wherein:

R_2 is H, C_1 to C_7 acyl, [[or]] C_1 to C_7 substituted acyl, phenyl, substituted phenyl, C_5 to C_6 heteroaryl, C_5 to C_6 substituted heteroaryl, napthyl or substituted napthyl,

R_6 is H, C_1 to C_8 alkyl, C_1 to C_8 substituted alkyl, C_7 to C_{12} alkylphenyl, [[or]] C_7 to C_{12} substituted phenylalkyl, carboxy, ester, amide, [[or]] C_1 to C_8 aminoacyl, or C_1 to C_8 alkoxy.

7 (Currently amended). [[A]] The compound according to ~~any of~~ claim[[s]] 1 ~~to 6~~ wherein said compound is capable of binding the NR3B1 receptor protein or a portion thereof according to SEQ ID NO. 3 or a mammalian homologue thereof.

8 (Currently amended). [[A]] The compound according to ~~any of~~ claim[[s]] 1 ~~to 6~~ wherein said compound is capable of modulating the activity of the NR3B1 receptor protein comprising antagonistic or agonistic effects.

9 (Currently amended). A method for prevention or treatment of a NR3B1 receptor protein or NR3B1 receptor protein homologue mediated disease or condition in a mammal comprising administration of a therapeutically effective amount of a compound according to formula (1), or pharmaceutical acceptable salts or solvates thereof,

formula (1)



wherein:

R_1 is phenyl, substituted phenyl, C_5 to C_6 heteroaryl, C_5 to C_6 substituted heteroaryl, napthyl or substituted napthyl,

R_2 is H, C_1 to C_8 alkyl, C_1 to C_7 acyl, [[or]] C_1 to C_7 substituted acyl, C_1 to C_8 substituted alkyl, C_7 to C_{12} alkylphenyl, [[or]] C_7 to C_{12} substituted phenylalkyl, C_3 to C_8 cycloalkyl, C_3 to C_8 substituted cycloalkyl,[[,]] C_5 to C_6 heteroaryl, or [C_5 to C_6]-heteroaryl-(C_1 to C_6)-alkyl, and

R_3 is H, C_1 to C_8 alkyl, C_1 to C_8 substituted alkyl, C_7 to C_{12} alkylphenyl, ~~or or~~ C_7 to C_{12} substituted phenylalkyl, halogen, C_1 to C_8 alkoxy, furanyl, substituted furanyl, thiazyl,

substituted thiazyl, carboxy, ester, amide or C_1 to C_8 aminoacyl ~~a compound according to any of claims 1 to 6~~

wherein the prevention or treatment is directly or indirectly accomplished through the binding of [[the]] said compound ~~according to any of claims 1 to 8~~ to the NR3B1 receptor protein or to the NR3B1 receptor protein homologue.

10 (Currently amended). [[A]] The method for prevention or treatment of a NR3B1 receptor protein mediated disease or condition according to claim 9 wherein the mammal is a human.

11 (Currently amended). A method for

i. regulating physiologies that are influenced by estrogenic response pathways in a mammal comprising modulating the activity of the NR3B1 receptor; ~~with a therapeutically effective amount of a compound according to any of claims 1 to 8.~~

ii. treating in a mammal a disease which is directly or indirectly affected by estrogen levels;

iii. treating cancer, osteoporosis, obesity, lipid disorders or a cardiovascular disorder or influencing fertility and reproductive health in a mammal;

and/or

iv. modulating the expression of a gene directly or indirectly controlled by NR3B1 in tissues of a mammal;

wherein said method comprises administering to a mammal in need of such regulation, treatment and/or modulation an effective amount of a compound according to formula (1), or pharmaceutical acceptable salts or solvates thereof,

formula (1)



wherein:

R_1 is phenyl, substituted phenyl, C_5 to C_6 heteroaryl, C_5 to C_6 substituted heteroaryl, napthyl or substituted napthyl,

R_2 is H, C_1 to C_8 alkyl, C_1 to C_7 acyl, [[or]] C_1 to C_7 substituted acyl, C_1 to C_8 substituted alkyl, C_7 to C_{12} alkylphenyl, [[or]] C_7 to C_{12} substituted phenylalkyl, C_3 to C_8 cycloalkyl, C_3 to C_8 substituted cycloalkyl,[[,]] C_5 to C_6 heteroaryl, or [C_5 to C_6]-heteroaryl-(C_1 to C_6)-alkyl, and

R_3 is H, C_1 to C_8 alkyl, C_1 to C_8 substituted alkyl, C_7 to C_{12} alkylphenyl, ~~or or~~ C_7 to C_{12} substituted phenylalkyl, halogen, C_1 to C_8 alkoxy, furanyl, substituted furanyl, thiazyl, substituted thiazyl, carboxy, ester, amide or C_1 to C_8 aminoacyl.

12 – 14 (Cancelled).

15 (Currently amended). The method of claim 11 ~~13 or 14~~,wherein said mammal is a human.

16 (Currently amended). The ~~Use of a~~ method according to claim 15 for treating cancer, osteoporosis, lipid disorders or a cardiovascular disorder in humans or influencing fertility and reproductive health.

17 (Currently amended). [[A]] The method according to claim [14] 11 wherein the expression of genes comprising aromatase, MCAD, thyroid receptor alpha, osteopontin, PS2, lactoferrin is modulated.

18-26 (Cancelled).

27 (New claim). A pharmaceutical composition comprising a compound according to formula (1), or pharmaceutical acceptable salts or solvates thereof,

formula (1)



wherein:

R_1 is phenyl, substituted phenyl, C_5 to C_6 heteroaryl, C_5 to C_6 substituted heteroaryl, napthyl or substituted napthyl,

R_2 is H, C_1 to C_8 alkyl, C_1 to C_7 acyl, [[or]] C_1 to C_7 substituted acyl, C_1 to C_8 substituted alkyl, C_7 to C_{12} alkylphenyl, [[or]] C_7 to C_{12} substituted phenylalkyl, C_3 to C_8 cycloalkyl, C_3 to C_8 substituted cycloalkyl,[[,]] C_5 to C_6 heteroaryl, or [C_5 to C_6]-heteroaryl-(C_1 to C_6)-alkyl, and

R_3 is H, C_1 to C_8 alkyl, C_1 to C_8 substituted alkyl, C_7 to C_{12} alkylphenyl, ~~or or~~ C_7 to C_{12} substituted phenylalkyl, halogen, C_1 to C_8 alkoxy, furanyl, substituted furanyl, thiazyl, substituted thiazyl, carboxy, ester, amide or C_1 to C_8 aminoacyl;

together with a pharmaceutical carrier.